Key Points
- Amphastar EVP Rong Zhou sold 10,000 shares for approximately $239,400, reducing their direct ownership by 5.58% to 169,203 shares. Zhou also sold 3,187 shares earlier in September.
- Amphastar reported quarterly EPS of $0.91, beating the $0.62 consensus estimate, while revenue of $183.9 million also exceeded expectations.
- Analyst sentiment remains cautious: the stock has a consensus “Reduce” rating and a $22.50 price target, compared with a recent share price of $23.82.
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Get Free Report) EVP Rong Zhou sold 10,000 shares of the company's stock in a transaction dated Wednesday, September 16th. The shares were sold at an average price of $23.94, for a total value of $239,400.00. Following the transaction, the executive vice president directly owned 169,203 shares in the company, valued at $4,050,719.82. This represents a 5.58% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
Rong Zhou also recently made the following trade(s):
- On Wednesday, September 2nd, Rong Zhou sold 3,187 shares of Amphastar Pharmaceuticals stock. The shares were sold at an average price of $23.63, for a total transaction of $75,308.81.
Amphastar Pharmaceuticals Stock Performance
Shares of Amphastar Pharmaceuticals stock opened at $23.82 on Friday. The company has a 50 day moving average price of $21.19 and a 200 day moving average price of $20.33. The firm has a market capitalization of $1.01 billion, a P/E ratio of 14.09, a PEG ratio of 4.61 and a beta of 0.92. The company has a quick ratio of 1.71, a current ratio of 2.40 and a debt-to-equity ratio of 0.79. Amphastar Pharmaceuticals, Inc. has a 52 week low of $16.65 and a 52 week high of $29.52.
Amphastar Pharmaceuticals (NASDAQ:AMPH - Get Free Report) last issued its quarterly earnings results on Thursday, August 6th. The company reported $0.91 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.62 by $0.29. The business had revenue of $183.90 million for the quarter, compared to analyst estimates of $179.92 million. Amphastar Pharmaceuticals had a net margin of 10.76% and a return on equity of 14.98%. Sell-side analysts expect that Amphastar Pharmaceuticals, Inc. will post 2.46 EPS for the current year.
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Bank of New York Mellon Corp acquired a new position in shares of Amphastar Pharmaceuticals in the 2nd quarter valued at about $4,689,000. Rice Hall James & Associates LLC grew its holdings in Amphastar Pharmaceuticals by 54.6% during the first quarter. Rice Hall James & Associates LLC now owns 187,348 shares of the company's stock worth $3,670,000 after acquiring an additional 66,172 shares during the period. Pacer Advisors Inc. raised its position in Amphastar Pharmaceuticals by 47.1% during the first quarter. Pacer Advisors Inc. now owns 261,483 shares of the company's stock valued at $5,122,000 after acquiring an additional 83,739 shares in the last quarter. Dimensional Fund Advisors LP raised its position in Amphastar Pharmaceuticals by 12.7% during the first quarter. Dimensional Fund Advisors LP now owns 2,027,947 shares of the company's stock valued at $39,726,000 after acquiring an additional 228,262 shares in the last quarter. Finally, Bank of America Corp DE lifted its holdings in Amphastar Pharmaceuticals by 36.0% in the first quarter. Bank of America Corp DE now owns 174,323 shares of the company's stock valued at $3,415,000 after acquiring an additional 46,149 shares during the period. 65.09% of the stock is currently owned by institutional investors and hedge funds.
Wall Street Analyst Weigh In
A number of brokerages recently issued reports on AMPH. Piper Sandler reduced their target price on Amphastar Pharmaceuticals from $21.00 to $20.00 and set a "neutral" rating for the company in a research note on Friday, August 7th. Barclays increased their price objective on Amphastar Pharmaceuticals from $20.00 to $23.00 and gave the company an "equal weight" rating in a report on Tuesday, August 18th. Bank of America restated an "underperform" rating and issued a $20.00 price objective (down from $25.00) on shares of Amphastar Pharmaceuticals in a research note on Monday, June 29th. Weiss Ratings reaffirmed a "sell (d+)" rating on shares of Amphastar Pharmaceuticals in a report on Wednesday, July 8th. Finally, Zacks Research upgraded Amphastar Pharmaceuticals from a "strong sell" rating to a "hold" rating in a research report on Tuesday, July 21st. Six investment analysts have rated the stock with a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, Amphastar Pharmaceuticals has a consensus rating of "Reduce" and a consensus price target of $22.50.
Get Our Latest Report on Amphastar Pharmaceuticals
About Amphastar Pharmaceuticals
(
Get Free Report)
Amphastar Pharmaceuticals, Inc is a biopharmaceutical company that develops, manufactures and markets injectable, inhaled and intranasal products. The company focuses on complex and technically challenging medicines, including products for diabetes, emergency medicine, respiratory conditions and other specialty-care applications.
Its marketed products include glucagon for treating severe hypoglycemia, BAQSIMI nasal glucagon, Primatene MIST for temporary relief of mild intermittent asthma symptoms, naloxone products for opioid overdose emergencies, and enoxaparin sodium injection, an anticoagulant.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
